Richard B Marchase Selected Research

Glucosamine (Dona)

2/2010	Increased O-linked beta-N-acetylglucosamine levels on proteins improves survival, reduces inflammation and organ damage 24 hours after trauma-hemorrhage in rats.
2/2009	Glucosamine improves cardiac function following trauma-hemorrhage by increased protein O-GlcNAcylation and attenuation of NF-{kappa}B signaling.
6/2008	Glucosamine protects neonatal cardiomyocytes from ischemia-reperfusion injury via increased protein O-GlcNAc and increased mitochondrial Bcl-2.
9/2007	Glucosamine administration improves survival rate after severe hemorrhagic shock combined with trauma in rats.
9/2007	Increased O-GlcNAc levels during reperfusion lead to improved functional recovery and reduced calpain proteolysis.
5/2007	Glucosamine cardioprotection in perfused rat hearts associated with increased O-linked N-acetylglucosamine protein modification and altered p38 activation.
4/2007	The protective effects of PUGNAc on cardiac function after trauma-hemorrhage are mediated via increased protein O-GlcNAc levels.
1/2007	Glucosamine protects neonatal cardiomyocytes from ischemia-reperfusion injury via increased protein-associated O-GlcNAc.
6/2006	Glucosamine administration during resuscitation improves organ function after trauma hemorrhage.
2/2006	Increased hexosamine biosynthesis and protein O-GlcNAc levels associated with myocardial protection against calcium paradox and ischemia.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Richard B Marchase Research Topics

Disease

7	Ischemia 06/2008 - 02/2006
6	Hemorrhage 02/2010 - 06/2006
6	Wounds and Injuries (Trauma) 02/2010 - 06/2006
6	Hyperglycemia 01/2007 - 12/2002
3	Shock 02/2010 - 06/2006
3	Reperfusion Injury 06/2008 - 01/2007
3	Hypertrophy 03/2008 - 04/2002
2	Hemorrhagic Shock 02/2009 - 09/2007
2	Necrosis 03/2008 - 01/2007
1	Inflammation (Inflammations) 02/2010
1	Myocardial Ischemia (Ischemic Heart Diseases) 02/2010
1	Ischemic Contracture 05/2007
1	Type 2 Diabetes Mellitus (MODY) 04/2007
1	Body Weight (Weight, Body) 04/2007
1	Diabetic Cardiomyopathies 04/2007
1	Hyperinsulinism (Hyperinsulinemia) 01/2007
1	Insulin Resistance 01/2007
1	Hyperlipidemias (Hyperlipidemia) 01/2007
1	Cardiomegaly (Heart Hypertrophy) 04/2002

Drug/Important Bio-Agent (IBA)

14	Proteins (Proteins, Gene)FDA Link 02/2010 - 12/2002
12	Glucosamine (Dona)IBA 02/2010 - 04/2004
10	HexosaminesIBA 04/2008 - 12/2002
9	AcetylglucosamineIBA 02/2010 - 06/2006
4	Glucose (Dextrose)FDA LinkGeneric 02/2010 - 01/2007
4	CalciumIBA 03/2008 - 04/2002
3	Angiotensin IIIBA 01/2007 - 04/2002
3	Phenylephrine (Neo-Synephrine)FDA LinkGeneric 01/2007 - 04/2002
3	AzaserineIBA 01/2007 - 12/2002
2	Mannitol (Osmitrol)FDA LinkGeneric 02/2010 - 09/2007
2	N-acetylglucosaminono-1,5-lactone O-(phenylcarbamoyl)oxime (PUGNAC)IBA 02/2010 - 04/2007
2	Glutamine (L-Glutamine)FDA Link 02/2010 - 01/2007
2	Inositol (Myoinositol)IBA 01/2006 - 04/2004
2	Transcription Factors (Transcription Factor)IBA 12/2002 - 04/2002
1	CarbamatesIBA 02/2010
1	Alanine Transaminase (SGPT)IBA 02/2010
1	Aspartate Aminotransferases (Aspartate Transaminase)IBA 02/2010
1	salicylhydroxamic acid (SHAM)IBA 02/2010
1	Insulin (Novolin)FDA Link 02/2010
1	L-Lactate Dehydrogenase (Lactate Dehydrogenase)IBA 02/2010
1	PotassiumIBA 02/2010
1	Interleukin-6 (Interleukin 6)IBA 02/2010
1	CytokinesIBA 02/2009
1	NF-kappa B (NF-kB)IBA 02/2009
1	Annexin A5IBA 03/2008
1	SolutionsIBA 09/2007
1	O-GlcNAc transferaseIBA 04/2007
1	Uridine Diphosphate (UDP)IBA 04/2007
1	hexosaminidase CIBA 01/2007
1	BuffersIBA 01/2007
1	Type C PhospholipasesIBA 04/2004
1	Adenosine Triphosphatases (ATPase)IBA 12/2002
1	ThapsigarginIBA 12/2002
1	Nuclear Localization Signals (Nuclear Localization Signal)IBA 12/2002
1	Calmodulin (Calcium-Dependent Activator Protein)IBA 04/2002
1	Atrial Natriuretic Factor (ANF)IBA 04/2002

Therapy/Procedure

6	Resuscitation 02/2010 - 06/2006
1	Intravenous Administration 04/2007